Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cogent BiosciencesCOGT 31 3-Year Book Growth Rate is 7.70% as of Jun. 2026. GuruFocus rates COGT with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,123 Biotechnology companies, Cogent Biosciences ranks better than 74.98% on this metric.
During the past 12 months, Cogent Biosciences's average Book Value per Share Growth Rate was 558.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 7.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -8.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Cogent Biosciences was 7.70% per year. The lowest was -28.40% per year. And the median was -15.70% per year.
Cogent Biosciences (NAS:COGT) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Cogent Biosciences 3-Year Book Growth Rate Related Terms
COGT vs ORKA, MIRM, DNTH: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Cogent Biosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's 3-Year Book Growth Rate falls into.
Cogent Biosciences 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 7.70% mean?
Cogent Biosciences (COGT) has a 3-Year Book Growth Rate of 7.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cogent Biosciences and its competitors. According to the industry distribution chart, Cogent Biosciences ranks #281 out of 1123 companies in the Biotechnology industry, placing it in the top 25%.
Is Cogent Biosciences' 3-Year Book Growth Rate too high?
Cogent Biosciences' current 3-Year Book Growth Rate is 7.70%. Based on the distribution chart, Cogent Biosciences ranks #281 out of 1123 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cogent Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' 3-Year Book Growth Rate compare to ORKA and MIRM?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #281 out of 1123 companies for 3-Year Book Growth Rate. This places Cogent Biosciences in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cogent Biosciences and its competitors. Cogent Biosciences's current 3-Year Book Growth Rate is 7.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current 3-Year Book Growth Rate of 7.70%. The current 3-Year Book Growth Rate is 7.70%. Cogent Biosciences' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current 3-Year Book Growth Rate is 7.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
31GF Score
Get the complete analysis for COGT
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
